Compare JOE & INDV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | JOE | INDV |
|---|---|---|
| Founded | 1936 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.7B | 3.7B |
| IPO Year | 2002 | 2014 |
| Metric | JOE | INDV |
|---|---|---|
| Price | $67.78 | $32.37 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 222.2K | ★ 3.0M |
| Earning Date | 04-22-2026 | 06-08-2026 |
| Dividend Yield | ★ 0.94% | N/A |
| EPS Growth | 56.69 | ★ 8100.00 |
| EPS | ★ 1.99 | 1.64 |
| Revenue | $513,246,000.00 | ★ $1,239,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.13 | ★ $19.68 |
| Revenue Growth | ★ 27.44 | 4.29 |
| 52 Week Low | $40.46 | $8.69 |
| 52 Week High | $73.54 | $38.00 |
| Indicator | JOE | INDV |
|---|---|---|
| Relative Strength Index (RSI) | 56.33 | 57.62 |
| Support Level | $66.26 | $31.70 |
| Resistance Level | $72.67 | $32.42 |
| Average True Range (ATR) | 2.07 | 1.17 |
| MACD | 0.51 | 0.38 |
| Stochastic Oscillator | 85.46 | 93.91 |
The St. Joe Co is a real estate development, asset management, and operating company and it has three operating segments; the Residential segment plans and develops residential communities and sells homesites to homebuilders or retail consumers, the Hospitality segment that derives maximum revenue, features a private membership club, hotel operations, food and beverage operations, golf courses, beach clubs, retail outlets, gulf-front vacation rentals, management services, marinas, and other entertainment assets, and Commercial segment include leasing of commercial property, multi-family, senior living, self-storage, and other assets and it also oversees the planning, development, entitlement, management, and sale of commercial and rural land holdings.
Indivior Pharmaceuticals Inc is a specialty pharmaceutical company singularly focused on delivering evidence-based treatment and advancing understanding of opioid use disorder (OUD) as a chronic but treatable brain disease. The company derives revenues from customers through the development, manufacture and sale of buprenorphine-based prescription drugs for treatment of opioid dependence and related disorders. The company's products include: Sublocade (buprenorphine extended-release monthly injection), and Suboxone (buprenorphine and naloxone sublingual film).